Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 11, 2013, Pages 2016-2023

  Hernandez, Brenda Y ^a   Zhu, Xuemei ^a   Kwee, Sandi ^a,b   Chan, Owen T M ^a,c   Tsai, Naoky ^c   Okimoto, Gordon ^a   Horio, David ^c   McGlynn, Katherine A ^d   Altekruse, Sean ^e   Wong, Linda L ^a,c  

^a UNIVERSITY OF HAWAII   (United States)

^b Queen's Medical Center   (United States)

^c UNIVERSITY OF HAWAII   (United States)

^d Div of Cancer Epidemiol and Genet   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FORMALDEHYDE; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; PARAFFIN; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; DISEASE ASSOCIATION; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PYROSEQUENCING; REGIONAL METASTASIS; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROLOGY; SURVIVAL TIME; VIRUS HEPATITIS;

CARCINOMA, HEPATOCELLULAR; FEMALE; HAWAII; HEPACIVIRUS; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84887299089     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0397     Document Type: Article

References (53)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002.CA Cancer J Clin 2005;55:74-108.
2. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: A population-based study. Gastroenterology 2004;127:1372-80.
3. Reis LAG, Melbert D, Krapcho M, StinchcombDG, Howlader N, Horner MJ, et al. SEER Cancer Statistics Review, 1975-2005. 2008; [cited 2013 Jan.] Available from: http://seer.cancer.gov/csr/1975-2005/.
4. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: An update. Ann Intern Med 2003;139:817-23.
5. Eheman C, Henley SJ, Ballard-Barbash R, Jacobs EJ, Schymura MJ, Noone AM, et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012;118:2338-66.
6. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al. SEER Cancer Statistics Review, 1975-2004. 2007; [cited 2013 Jan.] Available from: http://seer.cancer.gov/csr/1975-2004/.
7. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013;105:175-201.
8. Kulkarni K, Barcak E, El-Serag H, Goodgame R. The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States. Aliment Pharmacol Ther 2004;20:445-50.
9. Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, et al. Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol 2003;98: 2060-3.
10. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29:664-9.
11. Raza SA, Clifford GM, Franceschi S. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: A systematic review. Br J Cancer 2007;96: 1127-34.
12. Seeff LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene 2006; 25:3771-7.
13. El-Serag HB. Hepatocellular carcinoma: An epidemiologic view. J Clin Gastroenterol 2002;35:S72-8.
14. Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002;35:266-9.
15. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160: 3227-30.
16. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36: 1349-54.
17. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007;37 Suppl 2:S88-94.
18. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
19. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: A population based case control study. Gut 2005;54:533-9.
20. Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 2008;49:652-7.
21. Raimondo G, Caccamo G, Filomia R, Pollicino T. Occult HBV infection. Semin Immunopathol 2013;35:39-52.
22. Carreno V, Bartolome J, Castillo I, Quiroga JA. New perspectives in occult hepatitis C virus infection. World J Gastroenterol 2012;18: 2887-94.
23. Pham TN, Coffin CS, Michalak TI. Occult hepatitis C virus infection: what does it mean? Liver Int 2010;30:502-11.
24. Castillo I, Pardo M, Bartolome J, Ortiz-Movilla N, Rodriguez-Inigo E, de Lucas S, et al. Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 2004;189:7-14.
25. Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology 2011;54:434-42.
26. Kannangai R, Molmenti E, Arrazola L, Klein A, Choti M, Thomas DL, et al. Occult hepatitis B viral DNA in liver carcinomas from a region with a low prevalence of chronic hepatitis B infection. J Viral Hepat 2004; 11:297-301.
27. Fritz A, Percy C, Shanmugaratnam K, Sobin L, Parkin DM, Whelan, et al. The international classification of diseases for oncology. 3rd edition. Geneva, Switzerland: World Health Organization; 2000.
28. Goodman MT, Hernandez BY, Hewitt S, Lynch CF, Cote TR, Frierson HF Jr, et al. Tissues from population-based cancer registries: A novel approach to increasing research potential.HumPathol 2005;36:812-20.
29. Moon EJ, Jeong CH, Jeong JW, Kim KR, Yu DY, Murakami S, et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia- inducible factor-1alpha. FASEB J 2004;18:382-4.
30. Akhter S, Liu H, Prabhu R, DeLucca C, Bastian F, Garry RF, et al. Epstein-Barr virus and human hepatocellular carcinoma. Cancer Lett 2003;192:49-57.
31. Lindstrom A, Odeberg J, Albert J. Pyrosequencing for detection of lamivudine-resistant hepatitis B virus. J Clin Microbiol 2004;42: 4788-95.
32. Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugimura T, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A 1990;87:9524-8.
33. Svoboda-Newman SM, Greenson JK, Singleton TP, Sun R, Frank TS. Detection of hepatitis C by RT-PCR in formalin-fixed paraffin-embedded tissue from liver transplant patients. Diagn Mol Pathol 1997;6: 123-9.
34. Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics 2005;21:379-84.
35. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001;34:194-203.
36. Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: A hidden menace? Hepatology 2001;34:204-6.
37. Branco F, Mattos AA, Coral GP, Vanderborght B, Santos DE, Franca P, et al. Occult hepatitis B virus infection in patients with chronic liver disease due to hepatitis Cvirus and hepatocellular carcinoma in Brazil. Arq Gastroenterol 2007;44:58-63.
38. Shetty K, Hussain M, Nei L, Reddy KR, Lok AS. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl 2008;14:534-40.
39. Hassan ZK, Hafez MM, Mansor TM, Zekri AR. Occult HBV infection among Egyptian hepatocellular carcinoma patients. Virol J 2011; 8:90.
40. Wong DK, Huang FY, Lai CL, Poon RT, Seto WK, Fung J, et al. Occult hepatitis B infection and HBV replicative activity in patients with cryptogenic cause of hepatocellular carcinoma. Hepatology 2011; 54:829-36.
41. Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: A meta-analysis. Liver Int 2012;32:231-40.
42. Momosaki S, Nakashima Y, Kojiro M, Tabor E. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma. J Viral Hepat 2005;12:325-9.
43. McArdle MA, Finucane OM, Connaughton RM, McMorrow AM, Roche HM. Mechanisms of obesity-induced inflammation and insulin resistance: insights into the emerging role of nutritional strategies. Front Endocrinol 2013;4:52.
44. Chen Y, Wang X, Wang J, Yan Z, Luo J. Excess body weight and the risk of primary liver cancer: An updated meta-analysis of prospective studies. Eur J Cancer 2012;48:2137-45.
45. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al. Insulin resistance in chronic hepatitis C: Association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008;134:416-23.
46. Bugianesi E, Salamone F, Negro F. The interaction of metabolic factors withHCV infection: does it matter? J Hepatol 2012;56 Suppl 1:S56-65.
47. El-Zayadi AR, Anis M. Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. World J Gastroenterol 2012; 18:212-24.
48. Syed GH, Amako Y, Siddiqui A. Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metabol 2010;21:33-40.
49. Chen CL, Yang HI, Yang WS, Liu CJ, Chen PJ, You SL, et al. Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: A follow-up study in Taiwan. Gastroenterology 2008;135: 111-21.
50. Howlader N NA, Krapcho M, Neyman N, Aminou R, Waldron W, et al., editors. National Cancer Institute. Bethesda, MD: SEER Cancer Statistics Review, 1975-2008. Available from: http://seer.cancer.gov/csr/1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011.
51. Miller BA, Chu KC, Hankey BF, Ries LA. Cancer incidence and mortality patterns among specific Asian and Pacific Islander populations in the U.S. Cancer Causes Control 2008;19:227-56.
52. U.S. Census Bureau, 2011 American Community Survey. [cited 2013 Jan.] Available from: http://factfinder2.census.gov/faces/tableservices/jsf/pages/ productview.xhtml?src=bkmk.
53. Davila JA, Petersena NJ, Nelson HA, El-Serag HB. Geographic variation within the United States in the incidence of hepatocellular carcinoma. J Clin Epidemiol 2003;56:487-93.